Net product sales increased 12.4% to $67.4 million in the first fiscal quarter ended July 26 for Cyberonics, Inc. of Houston, TX. Including license revenue, sales were up 14.2% overall, with Europe in particular contributing a strong performance. Diluted earnings per share were adjusted by $0.17 cents due to a litigation settlement.
According to the Aug. 22, 2013 press release, “operating results for the first quarter of fiscal 2014 compared to the first quarter of fiscal 2013, and other achievements, include:
- Net product sales of $67.4 million, an increase of 12.4%;
- Net sales of $68.9 million (including $1.5 million of license revenue), an increase of 14.2%;
- Worldwide unit sales of 3,354, an increase of 9.8%;
- Record U.S. net product sales of $56.4 million, an increase of 10.8%;
- Strong International unit sales of 899, an increase of 20.8%;
- Adjusted non-GAAP income from operations increased by 21.9% to $21.0 million and adjusted non-GAAP income per diluted share increased by 27.9% to $0.48;¹
- Share repurchases of $13 million; and
- Significant progress in three clinical studies, E-36, E-37, and ANTHEM.”